CJC-1295 (No DAC) + Ipamorelin
GHRH(1-29) analog / selective GHRP
A paired formulation combining a growth-hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue, commonly studied together because they act on two distinct receptor systems that converge on the same pituitary GH-release pathway. This No-DAC variant of CJC-1295 is studied for a shorter, more physiologically pulsatile research profile than DAC-conjugated variants.
What researchers are studying CJC-1295 (No DAC) + Ipamorelin for.
Gh-Axis Stimulation
Selective Ghrelin-Receptor Signaling
Combined Pulsatile GH Signaling
Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2; CJC-1295 (No DAC): GHRH(1-29) analog — full sequence via certificate of analysis
Concentration and unit math, worked out.
Worked example for a 10mg vial reconstituted with 3mL of bacteriostatic water, drawn on a U-100 insulin syringe. Use the calculator below for any other vial size or water volume.
| UNITS DRAWN | VOLUME | DELIVERS |
|---|---|---|
| 5 units | 0.05 mL | 167 mcg |
| 10 units | 0.10 mL | 333 mcg |
| 20 units | 0.20 mL | 667 mcg |
| 30 units | 0.30 mL | 1000 mcg |
| 50 units | 0.50 mL | 1667 mcg |
Run your own numbers.
Pre-filled with a 30-day starting point — one vial, dosed once daily for 30 days. Adjust any field to match your own protocol.
RESULTS
Educational reference tool only — not medical advice. Reconstitution and dosing decisions for any research protocol should be reviewed with a qualified professional. Figures assume uniform mixing and standard syringe calibration; always verify against your own protocol.